Treatment of Fecal Incontinence After Obstetric Anal Sphincter Injuries (KISS)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
University Hospital of North Norway
ClinicalTrials.gov Identifier:
NCT01528995
First received: January 26, 2012
Last updated: May 15, 2014
Last verified: May 2014
  Purpose

Fecal incontinence (FI), the involuntary loss of solid or liquid stool, is a stigmatising condition. It can have a distressing impact and restriction on quality of life. Obstetric-related fecal incontinence may occur early after childbirth. Previous obstetric injury is a major cause of fecal incontinence in older women.

When conservative treatment fails, surgery may be an option. Both sacral nerve modulation and anal bulking injections is minimal invasive surgical alternatives. Step one in SNM is a trial period of temporary stimulation. If the test is successful, the patient can have an implantable stimulator (step 2). Transanal submucosal bulking injection of collagen is also a possible treatment option and can be an effective treatment for faecal incontinence.

The purpose of this study is to compare the efficacy of sacral nerve stimulation to anal bulking injections in women with fecal incontinence after obstetric sphincter injuries (OASIS), through a multicenter blinded, randomized controlled trial.


Condition Intervention
Fecal Incontinence
Device: Medtronic Interstim II-3058
Procedure: Anal bulking injection

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Blinded Randomized Controlled Clinical Trial Comparing Sacral Nerve Modulation and Anal Bulking Injections as Treatment for Fecal Incontinence After Obstetric Anal Sphincter Injuries (OASIS).

Resource links provided by NLM:


Further study details as provided by University Hospital of North Norway:

Primary Outcome Measures:
  • change in St Marks incontinence score [ Time Frame: 6 month after treatment ] [ Designated as safety issue: No ]
    Vaizey Incontinence Score A scale from 0-24 where 0 = perfect continence and 24 = complete incontinence. 3, 6 and 12 months


Secondary Outcome Measures:
  • change in number of fecal incontinence and urgency episodes per week [ Time Frame: 3 and 6 month after treatment ] [ Designated as safety issue: No ]
  • change in Quality of life assessment (Rockwood- Fecal incontinence quality of life ) [ Time Frame: 3 and 6 month ] [ Designated as safety issue: No ]
    change in FIQL and EQ-5D

  • change in urinary incontinence score (ICIQ-UI SF) [ Time Frame: 3 and 6 month ] [ Designated as safety issue: No ]
    International consultation on incontinence modular questionnaire, ICIQ-UI Short form, A scale from 0-21 where 0 = perfect continence and 20 = complete incontinence.

  • change in sexual function [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 84
Study Start Date: February 2012
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: sacral nerve modulation
Implantation of Interstim II-3058 impulse generator after positive PNE test. Randomized controlled trial.
Device: Medtronic Interstim II-3058
impulse generator
Active Comparator: anal bulking agents
anal injection with Permacol after positive PNE test. Randomized controlled trial.
Procedure: Anal bulking injection

Permacol injection:

four submucosal injections are administered at the 12, 3, 6 and 9 o'clock positions, above the level of the dentate line. The injection produces a bulge in the mucosa

Active Comparator: Anal bulking agents
Anal injection with Permacol after negative PNE test. cohort study.
Procedure: Anal bulking injection

Permacol injection:

four submucosal injections are administered at the 12, 3, 6 and 9 o'clock positions, above the level of the dentate line. The injection produces a bulge in the mucosa


Detailed Description:

Obstetric anal sphincter injuries (OASIS) is the most common cause of fecal incontinence (FI) in women. Obstetric-related FI may occur early after childbirth. Previous obstetric injury is also a major cause of FI in older women, and risk of FI increases with time and further childbirths. FI is involuntary loss of solid or liquid stool. Symptoms range from fecal urgency, soiling, to daily passive or urge fecal incontinence. FI is a stigmatizing condition. It can have a distressing impact and restriction on quality of life, including isolation and depression.

Tears during delivery is classified (Sultan) as first degree tears including vaginal epithelium, second degree tears into the perineal muscle, third degree involving the anal sphincter complex and fourth degree including sphincter complex and anorectal epithelium. OASIS includes third and fourth degrees tears.

First line of therapy of FI is conservative treatment including drug therapy and "biofeedback". If conservative treatment fails, surgery may be an option. Traditionally elective secondary sphincter repair has been performed at least once. Sphincter repair may improve symptoms in short time, but efficacy deteriorates with time.

Other minimal invasive surgical alternatives includes sacral nerve modulation (SNM) and anal bulking injection. Sacral nerve modulation involves stimulating the sacral nerves, usually S3 or S4. Step one is a trial period of temporary stimulation (PNE test). If the test is successful, the patient can have an implantable stimulator (step 2) to modulate sacral nerve function. SNM is also beneficial for treating FI after OASIS, and SNM is a alternative to secondary sphincter repair. SNM should possibly be preferred second line treatment also after sphincter tears related FI. Transanal submucosal bulking injection of collagen is also a possible treatment option and can be an effective treatment for both anal and fecal incontinence.

The purpose of this study is to compare the efficacy of sacral nerve modulation to anal bulking injections in women with fecal incontinence after OASIS through a Scandinavian multicenter single-blinded, randomized controlled trial.

To answer the research question, we will include 66-86 women with FI after OASIS. Sphincter defects are classified using three dimensional endoanal ultrasonography. Pelvic floor function including FI is registered using validated questionnaires. All women eligible for inclusion is PNE-tested for three weeks. The purpose of this cohort analysis, is to examine the possible effect of SNM in women with sphincter defects, and the hypothesis is that there is no relation between sphincter defect classified using tree dimensional ultrasound and efficacy of SNM.

Women with more than 50 % symptom reduction during PNE test (positive PNE test), is further randomized and allocated 1:1 into one of two arms with 28 participants. One group is allocated to implantation of permanent impulse generator, Interstim II-3058 and the other group is allocated to anal sub mucosal bulking injection of collagen, Permacol. The purpose of this study is to compare the efficacy of SNM to anal bulking injection. The hypothesis is that SNM provides a mean change in improvement in St Marks Incontinence score of more than 4 compared to the anal bulking group. This study is designed as a multicenter single-blinded, randomized controlled trial.

Women with less than 50 % symptom reduction (15-28, negative PNE test), is treated in a third arm with anal bulking injection. The purpose of this cohort study, is to examine the efficacy of anal bulking injection in women suffering from FI after sphincter tears, excluded from further treatment with SNM.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • fecal incontinence after OASIS
  • St Marks score > 8
  • failure of conservative treatment

Exclusion Criteria:

  • pregnancy
  • immunosuppressed
  • former major pelvic surgery or irradiation
  • Rectal prolapse
  • complex fistula
  • IBD
  • Lateral sphincterotomy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01528995

Locations
Norway
Dep. of Colorectal Surgery, University Hospital of North Norway
Tromsoe, Troms, Norway, 9037
Sponsors and Collaborators
University Hospital of North Norway
Investigators
Principal Investigator: Stig Norderval, PHD MD University Hospital of North Norway
  More Information

No publications provided

Responsible Party: University Hospital of North Norway
ClinicalTrials.gov Identifier: NCT01528995     History of Changes
Other Study ID Numbers: 2011//1300/REKnord
Study First Received: January 26, 2012
Last Updated: May 15, 2014
Health Authority: Norway: Regional Ethics Commitee
Norway: Data Protection Authority

Keywords provided by University Hospital of North Norway:
obstetric sphincter injuries
fecal incontinence
anal incontinence
OASIS
double incontinence
urinary incontinence
sexual function
sacral nerve modulation
sacral nerve stimulation
Interstim
anal bulking injections
Permacol

Additional relevant MeSH terms:
Fecal Incontinence
Wounds and Injuries
Rectal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on September 11, 2014